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Abstract
Study design Retrospective, longitudinal analysis of motor and sensory outcomes following thoracic (T2–T12) sensor-
imotor complete spinal cord injury (SCI) in selected patients enrolled into three SCI) registries.
Objectives To establish a modern-day international benchmark for neurological recovery following traumatic complete
thoracic sensorimotor SCI in a population similar to those enrolled in acute clinical trials.
Setting Afﬁliates of the North American Clinical Trial Network (NACTN), European Multicenter Study about Spinal Cord
Injury (EMSCI), and the Spinal Cord Injury Model Systems (SCIMS).
Methods Only traumatic thoracic injured patients between 2006 and 2016 meeting commonly used clinical trial inclusion/
exclusion criteria such as: age 16–70, T2–T12 neurological level of injury (NLI), ASIA Impairment Scale (AIS) A, non-
penetrating injury, acute neurological exam within 7 days of injury, and follow-up neurological exam at least ~ 6 months
post injury, were included in this analysis. International Standards for Neurological Classiﬁcation of Spinal Cord injury
outcomes including AIS conversion rate, NLI, and sensory and motor scores/levels were compiled.
Results A total of 170 patients were included from the three registries: 12 from NACTN, 64 from EMSCI, and 94 from
SCIMS. AIS conversion rates at approximately 6 months post injury varied from 16.7% to 23.4% (21.1% weighted average).
Improved conversion rates were observed in all registries for low thoracic (T10–T12) injuries when compared with high/mid
thoracic (T2–T9) injuries. The NLI was generally stable and lower extremity motor score (LEMS) improvement was
uncommon and usually limited to low thoracic injuries only.
Conclusions This study presents the aggregation of selected multinational natural history recovery data in thoracic AIS A
patients from three SCI registries and demonstrates comparable minimal improvement of ISNCSCI-scored motor and
sensory function following these injuries, whereas conversions to higher AIS grades occur at a frequency of ~20%. These
data inform the development of future clinical trial protocols in this important patient population for the interpretation of the
safety and potential clinical beneﬁt of new therapies, and the potential applicability in a multinational setting.
Sponsorship InVivo Therapeutics.
Introduction
Traumatic spinal cord injury (SCI) affects ~ 17,000 indi-
viduals each year in the United States [1], often resulting
in signiﬁcant impairments of motor, sensory, and auto-
nomic functions as well as substantial ﬁnancial burden.
Safe and effective treatment options to reduce the adverse
clinical consequences of the injury are highly needed. To
date, multiple therapies intended to neuroprotect or repair
the damaged spinal cord have been evaluated in clinical
trials [2], yet, none have achieved regulatory approval for
use in this patient population. One of the challenges
facing clinical development of promising treatments for
* James D. Guest
JGuest@med.miami.edu
1 InVivo Therapeutics Corporation, Cambridge, MA, USA
2 Kessler Institute and Rutgers University, West Orange, NJ, USA
3 Spinal Cord Injury Center, Balgrist University Hospital,
University of Zurich, Zurich, Switzerland
4 Department of Neurological Surgery, University of Louisville,
Louisville, KY, USA
5 Department of Neurosurgery, Houston Methodist Neurological
Institute, Houston, TX, USA
6 Department of Neurosurgery, University of Miami, Miami, FL,
USA
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
acute SCI is execution of clinical trials and interpretation
of the results. The rare incidence of SCI, paucity of
validated biomarkers and further patient segmentation
based on inclusion/exclusion criteria leads to substantial
challenges for trial enrollment and completion [3, 4]. In
light of these issues, early-phase open-label clinical
trials are typically conducted to assess both safety and
preliminary effectiveness, however interpretability of the
results is often difﬁcult. Conventionally designed acute
placebo-controlled trials require the enrollment of hun-
dreds of patients and take years to complete [5]. Future
acute SCI clinical trial efﬁciencies are needed to safely
and expeditiously advance the clinical development life-
cycle of investigational treatments. An example would be
the use of adaptive clinical trial designs [6] as proposed by
the ADAPT-IT (Adaptive Designs Accelerating Promis-
ing Treatments Into Trials) project [7]. In addition, reli-
able imaging [8] or injury biomarkers from serum are in
development [9] to more accurately stratify spinal cord-
injured persons.
The importance of real world data and its use in reg-
ulatory decision making has increased signiﬁcantly in recent
years [10]. In December 2018, the FDA published a frame
work for a Real World Evidence Program. https://www.fda.
gov/media/120060/download. Real world data can be used
to bolster the clinical evidence of the safety and effective-
ness of an investigational therapy. These data can come
from a variety of sources including electronic medical
records, claims, and billing activities, and importantly,
patient registries. Several SCI patient data registries exist
today that prospectively collect data documenting the nat-
ural history of recovery following injury. Three of those
registries are the Spinal Cord Injury Model Systems
(SCIMS), North American Clinical Trials Network
(NACTN), and the European Multicenter Study about
Spinal Cord Injury (EMSCI). These registries have been in
existence for several decades and collect patient data with a
broad geographic reach, including North America and
Europe. All three registries collect neurological-based
data including outcomes associated with the International
Standards for Neurological Classiﬁcation of Spinal Cord
Injury (ISNCSCI) as well as important functional
measures including the Spinal Cord Independence
Measure (SCIM) and Functional Independence Measure
(FIM). These are commonly used outcome measures in
acute SCI clinical trials. Data from these registries can be
used to understand the natural history of neurological or
functional improvement in this patient population.
Further, the patient data may be selected to match the most-
common clinical trial inclusion criteria. These changes are
critical in establishing what a minimal clinically
important difference (MCID) should be for any investiga-
tional therapy [11].
Previous literature describing the natural history of
recovery following acute SCI has been extremely valuable
to the ﬁeld. Reports that focus their analysis on recovery
following complete traumatic thoracic injuries are of parti-
cular importance, as clinical trials evaluating investigational
invasive therapies for acute SCI are typically initiated in this
patient population as the risk for neurological deterioration
and the functional implication of such loss is lower than at
cervical levels. Understanding the spontaneous rate of
recovery in this patient population is important when
assessing the safety and effectiveness of new therapies
[12–14] and in designing new clinical trials. Zariffa et al.
[15] reported an American Spinal Injury Association
[ASIA] Impairment Scale (AIS) conversion rate of 15.6% at
24 weeks following complete (AIS A) thoracic SCI using
data from the EMSCI registry. Similarly, Lee et al. [16]
published a 15.5% conversion rate at 1 year following
thoracic AIS A spinal cord injury using the SCIMS registry.
Furthermore, the Sygen clinical study database, which
enrolled 760 people including thoracic complete injuries,
has been a rich source of data over the past few decades
[17]. Multiple reports have been published summarizing the
results including changes in AIS grade, motor score, sen-
sory scores, as well as additional autonomic function out-
comes [17–20]. A recent report from NACTN examined the
natural history of recovery, including AIS conversion, fol-
lowing thoracic injury and reported a 14.3% conversion rate
[21]. Collectively, these reports have helped to set a
benchmark in the SCI community around the expected rate
of neurological improvement following thoracic AIS A
traumatic injuries. A recent summary of previous studies
reported that the overall conversion rate noted in thoracic
injuries was 30.6% [20]. However, a diversity of studies
included in this review did not require an early examination
and follow-up varied from 3 to 12 months.
Despite these reports, some previous natural history
recovery rates have limited utility for designing and inter-
preting modern day clinical trials. Previous papers reporting
on the natural history of recovery in thoracic AIS A injuries
included all-comers entered to their registries in their ana-
lysis. However, that breadth is not the case with clinical trial
patient selection. Generally, age range is conﬁned, pene-
trating injuries are excluded, and other ﬁltering criteria are
applied in clinical trials in attempts to isolate a more
homogenous population that is not at an increased safety
risk for participating in a clinical trial. Thus, the rate of
recovery in an all-comer population is likely not the same as
a more selected clinical trial patient cohort due to the
potential presence of greater diversity in prognostic vari-
ables. In addition, there has been a major evolution in
standard of care with a recommendation toward early sur-
gery [22] and subsequent earlier mobilization. Although the
inﬂuence that decompressive surgery has on neurological
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recovery remains incompletely understood, contemporary
benchmark data should be limited to a recent time frame
and ensure standard of care treatment was performed. Last,
the neurological exam to assess SCI patients has also
changed over time making it inappropriate to compare
modern day trial results with historical data [23, 24]. There
is a signiﬁcant need to provide contemporary benchmark
data for thoracic AIS A patients that approximate clinical
trial eligibility in order to better interpret clinical data
coming out of early phase, open-label studies as well as aid
in the design of late-stage clinical studies.
Here we present for the ﬁrst time a compilation of con-
temporary, ISNCSCI-based neurological recovery data from
three established SCI registries: NACTN, EMSCI, and
SCIMS. Patients included in the analysis represent those
that best match individuals entered into clinical trials and
were treated with modern day standard of care. This effort is
aimed at developing a robust comparator group to which
data from interventional clinical studies in thoracic AIS A
patients can be benchmarked. It is our intention that these
ﬁndings will guide the development of future clinical trial
protocols as well as aid in the interpretation of the safety
and potential clinical beneﬁt of new therapies.
Methods
Data sources
The selection of subjects for clinical trials is based on
deﬁned inclusion and exclusion criteria. The most-
commonly applied longitudinal measure is the ISNCSCI
[25]. The research question was to determine the proportion
of selected subjects with traumatic thoracic SCI that have an
initial motor complete AIS A injury and subsequently
experience a change in their AIS grade. Only spinal cord
levels, T2–T12 (and not L1) were included. To conduct the
analysis, three major SCI databases were speciﬁcally
queried, NACTN, EMSCI, and SCIMS in accordance with
their data release policies to provide the requested dei-
dentiﬁed data. These registries collectively provide the most
comprehensive and robust collection of longitudinal data
describing the natural functional recovery of patients fol-
lowing traumatic SCI. Summaries of each organization’s
registry are listed below. Each of these registries applies the
ISNCSCI exam rigorously requiring that personnel con-
ducting neurological exams are trained to conduct the
ISNCSCI [26]. In the time period 2006–2016, the most-
substantial update to ISNCSCI was published in 2011 and a
revised worksheet in 2013, and an update in 2015. How-
ever, the deﬁnition of a neurologically complete (AIS A)
injury did not change and remained based upon the sacral
sparing criteria [27].
NACTN
NACTN is an initiative of the Christopher Reeve Paralysis
Foundation. Funding to maintain the Registry
(NCT00178724) has been obtained from the US Depart-
ment of Defense. The participating centers have been civi-
lian and military academic neurosurgical hospitals, of which
there are currently 12. The registry collects initial clinical
status, demographics, detailed medical history, classiﬁca-
tion of neurological, and bony injury, the type and timing of
surgical therapy, adverse events and magnetic resonance
imaging data. The Registry seeks to establish the natural
history of recovery using standardized and validated mea-
sures, to facilitate scholarly research, and to serve as a
comparison group in clinical trials [28]. The enrollment of
subjects occurs as soon after injury as feasible based on
obtaining consent to participate in data collection and
follow-up. To be enrolled, consent must be obtained, and
the subject must be cognitively capable of undergoing the
detailed neurological testing that is employed. The registry
currently has data on 938 participants. Those people with
SCI who cannot be accessed owing to complex polytrauma,
signiﬁcant head injury, or other altered mental status are not
included. Research coordinators who conduct the ISNCSCI
and other exams are systematically trained. The data are
reviewed frequently for inconsistencies or errors and these
are corrected.
EMSCI
The aim of the EMSCI project is to establish a multicenter
basis for future therapeutic interventions in human SCI. The
registry (NCT01571531) was established in 2001 and cur-
rently includes over 4500 participants at ~ 18 European
centers. EMSCI includes a data quality management system
and is ISO 9001 certiﬁed demonstrating the organization’s
commitment to quality. Participants undergo an acute exam
with follow-up assessments performed by trained examiners
at 4, 12, 24, and 48 weeks. The examinations consist of a
standard set of neurological and functional assessments
(www.emsci.org) [29].
SCIMS
The SCIMS program was founded in 1970 and during this
time, 30 hospitals have served as sites for data collection.
More recently, during the 2011–2016 funding cycle,
14 sites in the United States were designated as SCIMS
centers. The database was formed in 1975 to collect, man-
age, and analyze the large amount of data the sites were
collecting. Currently, the registry includes approximately
45,000 people with SCI, of whom ~29,000 had one or more
follow-up records. Form I data include demographic
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information and acute care/diagnosis information. Form II
data include sociodemographic and outcome data of Form I
participants obtained at follow-up [30]. These data are
reviewed for inconsistencies or errors and these are
corrected.
Patient inclusion
Patient selection conditions were approximately similar to
typical acute SCI clinical trial inclusion/exclusion criteria.
In addition, the selection conditions were similar between
registries to the extent that the relevant data ﬁelds were
captured for each data source. Table 1 illustrates the
inclusion/exclusion criteria for each registry. Brieﬂy, for
each registry patients were included if they provided
informed consent, sustained a traumatic SCI between 2006
and 2016, were between the ages of 16 and 70, were clas-
siﬁed with a thoracic (T2–T12 neurological level of injury
[NLI]), complete (AIS A) injury within 7 days of injury,
and had follow-up neurological data beyond approximately
6 months post injury. Six months post injury was selected as
an appropriate follow-up duration as this is when neurolo-
gical recovery generally plateaus and it is the primary
endpoint time for many clinical trials [16]. Those persons in
the registries not meeting these criteria are not included in
this analysis. Additional criteria included patients that
underwent acute spinal surgery and excluded patients with
penetrating injuries.
Outcome measures
For this analysis, ISNCSCI-based outcome measures are
presented including AIS grade conversion, change in NLI,
and changes in motor and sensory scores. The ISNCSCI
neurological exam is the most-commonly utilized exam to
classify spinal cord injuries [23]. In brief, AIS grade is a
component of the ISNCSCI exam and remains a widely
used outcome measure in SCI clinical trials, particularly
those that enroll only thoracic-level injuries. The assessment
of complete (AIS A) versus incomplete (AIS B, C, or D)
injuries relies solely on the absence or presence, respec-
tively, of sacral sparing [31]. Sacral sparing is measured by
sensory testing (light touch and pin-prick) of the well-
deﬁned S4–5 dermatome as well as deep anal pressure of
the anorectal wall and voluntary anal contraction (VAC).
Next, the NLI signiﬁes the most caudal segment of the
spinal cord with normal sensory and motor level on both
sides of the body. For the majority of thoracic-level SCI
patients, the NLI is determined solely on sensory testing of
thoracic dermatomes. Negative NLI changes imply rostral
deterioration, whereas positive NLI changes signify caudal
improvement. Motor testing evaluates 10 myotomes bilat-
erally with each myotome receiving an ordinal score of 0–5.
The maximum total motor score for both upper and lower
extremities is 100. It is fairly common for thoracic AIS A
patients to have intact upper extremity motor scores of 50
and lower extremity motor scores of 0 unless there are
upper extremity fractures or nerve injuries to diminish the
motor score or a large zone of partial preservation in the
lower extremities to increase the score. At last, sensory
testing consists of measuring 28 dermatomes bilaterally
using two different stimuli (light touch (LT) and pin-prick
(PP)) to assess the dorsal columns and spinothalamic tract.
Statistical methods
All results are presented using descriptive statistics with no
a priori hypothesis testing planned or performed. All sum-
mary results are presented for each patient that met criteria
from each registry and aggregated where appropriate. Fur-
ther, as NLI is a known prognostic variable [15, 32], AIS
conversion rate and motor scores are presented using an
NLI stratiﬁcation scheme of T2–T5, T6–T9, and T10–T12
patients. The overall weighed average conversion percen-
tage was calculated as NACTN conversion % (12)+
EMSCI conversion % (64)+ SCIMS conversion %
(75)/170.
Results
Patient demographics
A total of 170 patients from the three registries were
included in this analysis: 12 from NACTN, 64 from
EMSCI, and 94 from SCIMS (Table 2). 76.5% (n= 130) of
the patients were male. The average age at injury ranged
from 35.5 years old (SCIMS) to 44.7 years old (NACTN).
Patients in the NACTN registry received their baseline
ISNCSCI exam at ~16 h post injury on average. It has been
Table 1 Inclusion/exclusion criteria for patient selection from each
registry
NACTN EMSCI SCIMS
Traumatic injuries only ✓ ✓ ✓
Injured between 2006 and 2016 ✓ ✓ ✓
Baseline ISNCSCI exam (days post
injury)
≤ 4 ≤ 7 ≤ 4
Baseline NLI= T2–T12 ✓ ✓ ✓
AIS A ✓ ✓ ✓
Age 16–70 ✓ ✓ ✓
Follow-up ISNCSCI exam (months
post injury)
5–7 5–6 6–18
Exclude penetrating injuries ✓ < 1% ✓
Spinal surgery required (acute) ✓ > 90% ✓
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reported that acute ( <24 h post injury) ISNCSCI exams are
reliable if the patient does not exhibit factors such as closed
head injury or serious intoxication, which are typical
exclusion criteria for clinical trials [33]. EMSCI patients
had their baseline neurological exam conducted at 3.8 days
post injury on average. Patient selection from the SCIMS
registry required that individuals had a baseline ISNCSCI
exam within 4 days of injury and the patients from the
registry included in this study had their baseline neurolo-
gical exam conducted at 1.6 days post injury on average. Of
note, however, although the motor exam and AIS was
obtained at this early time period, the SCIMS database
calculates changes in sensory score as the difference at
follow-up from rehabilitation admission, which is ~ 2 weeks
post injury in this patient population.
Patients from the EMSCI and SCIMS registries had very
similar NLI distributions. NLI is a known predictive factor
of recovery with lower level injuries more prone to
experience neurological improvement [15, 16, 34]. NACTN
had a decreased portion of T10–T12 injuries (16.7%), this
should be considered when interpreting summary data. This
does not align with the epidemiology of SCI and is likely
owing to the small sample size or patterns of practice.
Follow-up neurological exam
All patients were required to have a follow-up neurological
exam beyond approximately 6 months post injury. Each
registry has different longitudinal follow-up criteria. Details
for when the follow-up ISNCSCI exam occurred for
patients from each registry is as follows. Data used for
patients within the NACTN registry were collected on
average at 184 days (median: 181.5 days) post injury.
Similarly, EMSCI patients were evaluated, on average, at
167 days (median: 168 days) post injury. Conversely, the
SCIMS registry captures their Year 1 follow-up data at
12 months post injury with a 6-month tolerance. Follow-up
data from SCIMS presented here were obtained, on average,
at 358 days (median: 361 days) post injury. Although
neurological conversion usually occurs early post injury and
recovery typically plateaus at ~ 6 months, the difference in
follow-up exam timing is important to note when compar-
ing results between registries.
AIS conversion
AIS conversion rates were approximately similar between
the three registries (Figure 1a); 16.7% (2/12), 18.8%
(12/64), and 23.4% (22/94) of the patients in the NACTN,
EMSCI, and SCIMS registries, respectively, experienced an
AIS grade conversion at follow-up visit. The weighted
average AIS conversion rate for all registries combined was
21.1% (36/170, 95% CI 15.7–28.0%). The rate of AIS grade
improvement was greater with lower level injuries (e.g.,
T10–T12). In all, 29.3% of these patients experienced an
AIS grade conversion compared with 16.0% of T6–T9
patients and 13.3% of T2–T5 patients.
AIS grade improvement rates to either sensory incom-
plete (AIS B) or motor incomplete (AIS C) were similar
between EMSCI and SCIMS (Fig. 1b). The two patients
Table 2 Demographic information and baseline data for patients
included in the analysis from each respective registry
NACTN EMSCI SCIMS
Patients included 12 64 94
Date of
injury (%)
2006–2008 33.3 31.3 34.0
2009–2012 50.0 39.1 34.0
2013–2016 16.7 29.7 31.9
Age at injury 44.7 ± 11.9 38.7 ± 13.1 35.5 ±14.2
% Male 83.3 78.1 74.5
Time to baseline ISNCSCI
exam (days)
0.7 ± 0.9 3.8 ± 2.4 1.6 ±1.3
Baseline
neurological
level of
injury (%)
T2–T5 33.3 26.6 25.5
T6–T9 50.0 26.6 28.7
T10–T12 16.7 46.9 45.7
T2-T12
NACTN
n=12
EMSCI
n=64
SCIMS
n=94
All Registries
T2-T5 T6-T9 T10-T12
n=170 n=45= n=50 n=75++
Fig. 1 a AIS conversion rate for all patients (T2–T12) in each registry
as well as a combined weighted average. AIS conversion rate for
patients combined from each registry stratiﬁed by their baseline NLI
(T2–T5, T6–T9, T10–T12). b Degree of AIS conversion, if any, to
AIS B (A→ B), AIS C (A→ C), or AIS D (A→D)
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that experienced an AIS grade conversion in the NACTN
registry improved to AIS C; one patient had no VAC but a
+ 1 LEMS and the other patient has no LEMS improvement
but had regained VAC. Improvement to AIS D in this
patient population is very rare with only ﬁve (2.9%)
patients, all from the SCIMS registry, with injuries in the
T10–T12 region, doing so.
Change in NLI
The majority of patients experienced minor changes in NLI
(Figure 2a). In all, 33.7% of patients experienced a positive
NLI change (i.e., caudal improvement), whereas 28.4% of
individuals were documented to have a negative NLI
change (i.e., rostral deterioration). Only 5.9% of all patients
had an ascent of NLI of more than two levels. Although
small variations in thoracic dermatomal levels have little
effect on the patients function and QoL, these data are
important to understand when evaluating the safety of
investigational therapies that may transition to cervical
level patients.
Change in sensory scores
The change in sensory scores (PP and LT) were similar
between all three registries (Fig. 2b). The median change in
scores was positive for patients in all registries with the
exception of the change in LT scores for patients from the
SCIMS registry (median ΔLT= 0).
Change in total motor score
A majority portion of the patients in all three registries
experienced no change in total motor score (Fig. 3a). If
improvement did occur, it was most likely to be a relatively
small change between 1 and 5 motor points. Only 10.6% of
the total patients (18/170) experienced a motor score
improvement of >10 points with the majority of those
patients (14/18) having T10–T12 baseline NLIs. Only two
patients, from the SCIMS registry, experienced a motor
score loss. These individuals were high level thoracic
(T2–T5) injuries and lost upper extremity motor points.
Improvement in motor score is correlated to baseline NLI
with limited average improvement in T2–T5 injuries (mean:
0.39 points) and increased improvement in T10–T12 inju-
ries (mean: 4.26 points). The median change in total motor
score was 0 within all registries and within all NLI strata.
Only the 75% percentile within the T10–T12 patients in the
EMSCI and SCIMS registries were non-zero with gains of
3.5 and 11 motor points, respectively.
Discussion
This analysis provides a modern benchmark for expected
changes in standardized outcomes after traumatic thoracic
complete SCI. Here, we queried three established SCI
registries to model selection of clinical trial eligible patients
and assess their neurological changes at 6 months (or
beyond) post injury. Emphasis was placed on maintaining
consistency in the inclusion/exclusion criteria for each
registry to maximize the interpretability of cross-registry
comparisons. However, this was not fully achieved in all
cases owing to variability between registries. For example,
all patients included from the NACTN and SCIMS regis-
tries had their baseline neurological exam performed within
4 days of injury, whereas patients included from the EMSCI
registry had their baseline exam performed within 7 days of
injury (median: 4.0 days). Although the reliability of acute
ISNCSCI exams has been reported [33], additional work is
needed to understand the stability of early neurological
exams following traumatic injury. Also, post injury follow-
up time was consistent for patients from the NACTN and
EMSCI registries (5–7 months), however, SCIMS Form II
data collection occurs at 1 year ± 6 months post injury.
PP LT
PP
LT
LTPP
n=11 n=9
n=62
n=62
n=36 n=37
Fig. 2 a NLI change. Negative integers indicate rostral deterioration
and positive integers indicate caudal improvement. Zero indicates no
change. b Change in sensory scores for both pin-prick (PP) and light
touch (LT) for patients in each registry. Box-and-whisker plot indi-
cates min-max and 25th, 50th, and 75th percentiles. Note: the SCIMS
database calculates changes in sensory score as the difference at
follow-up from rehab admission which is approximately 2 weeks post
injury in this patient population
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AIS grade conversion is the most commonly used clin-
ical endpoint for thoracic SCI trials because this reﬂects
recovery of long tract functions. Improvement in AIS A
grade to incomplete injuries, including AIS B, has been
correlated to bladder/bowel awareness, decrease in inci-
dence of pressure ulcers [35, 36], and decreased re-
hospitalizations [31, 37]. Here, we report a 21.1% pooled
AIS conversion rate, which slightly exceeds some of the
previous published literature [15, 16, 38]. The higher rates
of AIS conversion, particularly in T2–T5, may reﬂect
changes in modern care that emphasize decompressive
surgery, support of blood pressure, and very careful trans-
fers to avoid iatrogenic exacerbation. Further, as previously
reported, patients with T10–T12 injuries have a more-
favorable prognosis for AIS conversion. This information is
critically important to recognize in the design of clinical
trials and interpretation of the resulting clinical data. The L1
level was not included as injuries at this level may be a
mixture of conus and root injury, are generally burst frac-
tures that are often managed conservatively [39], and have a
better natural history for recovery [40, 41].
Although small changes in NLI following thoracic
injuries lead to little clinical or QoL impact, it is important
to accurately document these changes as these data could be
useful in assessing a therapeutics risk/beneﬁt. Therefore,
there is a need to maintain high inter- and intrarater accu-
racy and consistency, especially when considering multi-
center clinical trials. In complete thoracic injuries, NLI is
typically dictated by sensory level solely as motor testing is
not currently conducted in this anatomical region. To
minimize the subjectivity associated with sensory testing as
well as variations in dermatomal mapping [42], it may be
useful to physically mark the observed sensory levels and
photograph them in order to be more certain of NLI changes
[43]. At last, the absence of motor testing from T1 to L1
represents a gap in classiﬁcation and measures of trunk
functions [44] need further development by the SCI com-
munity in order to understand the clinical meaningfulness of
level-by-level improvement in the thoracic patients.
Motor improvement is uncommon following thoracic
AIS A injuries that precludes its use as a preferred outcome
measure in this patient population in the absence of a
therapeutic with a large effect size. Although motor
improvement is a desired clinical outcome, it is not of the
highest priority for paraplegics [45], further supporting the
use of alternative primary outcome measures.
These data presented herein, collectively, can be used to
help interpret the safety and preliminary effectiveness of novel
therapeutics in early-stage clinical trials. Further, this infor-
mation can help guide the design of follow-on trials. Based on
a 21.1% standard of care AIS conversion rate including all
thoracic (T2–T12) levels, a randomized controlled clinical trial
designed to show a 20% AIS conversion rate difference,
which one prior study published as a potential MCID [4],
would have to enroll approximately 80 subjects in each group
(α= 0.05, β= 0.80). Based on previous clinical trial enroll-
ment rates in this patient population, a trial of that size would
be difﬁcult to execute, and alternative trial designs may be
needed to advance treatment options in this area of signiﬁcant
unmet medical need. However, the good comparability of
changes in the thoracic AIS A patients across the different SCI
networks based in American and European countries indicates
that multinational trials in this patient population should be
feasible and reliable. The MCID after SCI remains without
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clear deﬁnition, especially for thoracic injuries where seg-
mental recovery has less impact [11]. Conversion to AIS B or
higher has been linked to less frequent and lengthy hospita-
lizations, which could be perceived to increase quality of life
[37]. In a multiple Logit model regression, it was found that
odds ratios for important aspects of daily life differed between
AIS A and AIS B subjects, for example AIS B subjects less
frequently had indwelling catheters at discharge from rehabi-
litation and at one year follow-up [31].
This analysis comes with various limitations. First,
patients included in this analysis were required to have a
follow-up neurological exam, therefore those that were lost
to follow-up were excluded. This introduces bias into the
natural history data presented here although the exact
impact is unknown. Also, this is different from a typical
clinical trial where all efﬁcacy analyses are conducted on
the intent to treat group, which includes all patients ran-
domized even if they subsequently withdraw or are lost to
follow-up. The withdrawal or lost to follow-up rates from
the registries are not reported here but are likely higher than
what one would expect in a clinical trial. Also, it was not
possible to maintain fully consistent inclusion/exclusion
criteria for patients across registries owing to the different
data ﬁelds each organization collects. To identify a more
homogenous patient population, similar to clinical trials, it
is recommended that the organizations collaborate to ensure
critical demographic information, mechanism of injury, and
outcomes data are collected at consistent time points to
allow for better registry to registry comparison and com-
pilation. We see this work as an initial product of colla-
boration across the three registries. Data sharing is complex
between established registries and here only aggregate data
from SCIMS and EMSCI was provided. Some of the bar-
riers have been articulated [46] and a further effort is
underway to facilitate inter-registry data sharing known as
the International Spinal Data Network.
In conclusion, this study presents the aggregation of
recovery data in thoracic AIS A patients from three multi-
national SCI registries and demonstrates comparable minimal
improvement of motor and sensory function following these
injuries, whereas conversions to higher AIS grades occur at a
frequency of ~20%. These data inform the development of
future clinical trial protocols in this patient population for the
interpretation of the safety and potential clinical beneﬁt of
new therapies, and the potential applicability in a multi-
national setting. Future studies may reﬁne this conversion
rate, but it is consistent with numerous improvements in
clinical practice before and during the study period.
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